Information intended for healthcare professionals. This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Please see the bottom of the page for full disclaimer.
If the PDF does not load within 5 seconds, please refresh the page.
For additional information consult:
- SmPC for Xarelto (rivaroxaban): www.medicines.org.uk/emc/product/2793
- For further resources relating to rivaroxaban and NVAF: www.xarelto-info.co.uk/hcp
- For patient information leaflets: www.af-patient-booklet.co.uk
*Rivaroxaban is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.
HCP=healthcare professional; NVAF=non-valvular atrial fibrillation; SmPC=summary of product characteristics
This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Bayer plc carried out approval to ensure compliance with regulations. No part of this publication may be reproduced in any form without the permission of the publisher.
Date of preparation: June 2020